세계의 주의력결핍 과잉행동장애(ADHD) : 기회 평가 및 예측(2022-2032년)
Attention Deficit Hyperactivity Disorder (ADHD): Opportunity Assessment and Forecast 2022-2032
상품코드
:
1494279
리서치사
:
GlobalData
발행일
:
2024년 05월
페이지 정보
:
영문 75 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
주요 7개국 시장의 ADHD 환자 수는 21,141,036명에서 21,970,997명으로 증가하여 예측 기간 동안 0.4%의 연간 성장률(AGR)을 기록할 것으로 예상되며, 2022년 기준 ADHD 시장 규모는 119억 달러에 달할 것으로 예상됩니다.
10년의 예측 기간 동안 시장은 0.9%의 마이너스 연평균 성장률(CAGR)로 감소하여 2032년에는 109억 달러 규모에 이를 것으로 예상됩니다. 이러한 감소의 주요 요인은 예측 기간 내에 브랜드 제품의 특허가 만료되고 저렴한 제네릭 의약품이 시장에 진입할 것으로 예상되기 때문입니다. 또한, 시장은 2027년까지 지속될 것으로 예상되는 주요 약품군의 원료의약품 부족의 영향을 크게 받고 있습니다.
이 보고서는 주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 스페인, 영국, 일본)의 주의력결핍과잉행동장애(ADHD) 시장을 조사했으며, 2032년까지 동향, 역학 개요, 제품 프로파일, 미충족 수요 및 기회 등을 정리하여 전해드립니다.
목차
- 약어
- 관련 보고서
- 주요 요약
- 질환 개요
- ADHD 개요
- ADHD SWOT 분석
- ADHD 진행
- ADHD 진단과 분류
- 역학
- 2022-2032년 ADHD 진단 환자 수(남성 및 여성)
- ADHD 유병률(2022년), 성별
- 남성 및 여성 ADHD 진단 유병률(2022년)
- ADHD 진단 증례 수, 남성 및 여성(2022년) 중증도별
- 정보 출처와 조사 방법 : ADHD로 진단 유병률 높은 증례
- 정보 출처와 조사 방법 : 증상별 진단 ADHD 유병률
- 정보 출처와 조사 방법 : 중증도별 ADHD 진단 사례
- 현재의 치료 옵션
- 치료 패러다임
- 현재의 치료 옵션
- 현재의 치료 옵션 : KOL의 견해
- 제품 개요 : Amphetamines (Vyvanse, Adderall, Mydayis, Dyanavel, Adzenys, Evekeo, Dexedrine, Xelstrym)
- 제품 개요 : Methamphetamines (Desoxyn)
- 제품 개요 : Methylphenidates (Concerta, Daytrana, Metadate CD, Methylin, Ritalin, Medikinet, Jornay PM, Aptensio XR, Quillivant XR, QuilliChew, Relexxii, Cotempla XR-ODT, Azstarys, Focalin)
- 제품 개요 : Alpha-2A Adrenergic Agonists (Intuniv; guanfacine hydrochloride ER)
- 제품 개요 : Noradrenergic Reuptake Inhibitors (Strattera and Qelbree)
Unmet Needs and Opportunities
- 미충족 요구와 기회
- ADHD 미충족 요구
- 자극제와 동등 효능 개요를 가지는 비자극제
- 수면을 방해하지 않고 야간도 커버할 수 있는 제품
- 일반적인 ADHD 합병증 이중 증상 완화를 제공하는 제품
- 처방 의식 향상과 교육
- 연구개발 전략
- ADHD 임상시험 디자인 동향
- ADHD 거래 동향
- 파이프라인 평가
- ADHD 파이프라인 개요
- ADHD 치료제 개발 후기 단계
- 제품 개요 : Cingulate Inc's CTx-1301
- 제품 개요 : Axsome Therapeutics Inc's Solriamfetol Hydrochloride
- 제품 개요 : Otsuka Pharmaceutical Co's Centanafadine SR
- 제품 개요 : Neurocentria Inc's NRCT-101SR
- ADHD : 임상시험(제II/III상) 개요
- 시장 전망
- ADHD 시장 예측
- 시장 성장 촉진요인과 억제요인
- 시장 성장 촉진요인과 억제요인 : 세계의 ADHD 치료제 부족
부록
LSH
영문 목차
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Attention Deficit Hyperactivity Disorder (ADHD) market through 2032.
The prevalent cases of ADHD in the 7MM will increase from 21,141,036 to 21,970,997, at an annual growth rate (AGR) of 0.4% over the forecast period. The ADHD market was valued at $11.9 billion in the 2022 baseline year.
Over the 10-year forecast period, the market is projected to decline at a negative compound annual growth rate (CAGR) of 0.9%, to $10.9 billion by 2032. The major driver for this decline is patent expiry and entry of cheap generic alternatives of branded products within the forecast period. In addition, the market has been heavily affected by shortages of active pharmaceutical ingredients (APIs) of key drug classes, which are anticipated to last until 2027.
Key Highlights
- Report deliverables include a Pdf report and an Excel-based forecast model
- Forecast includes the 7 major markets (7MM)
- Forecast covers the period 2022-2032.
- 2022 base year sales within the ALS market are approximately $11.9 billion across the 7MM detailed in this report. GlobalData estimates that the ALS market will decline at a negative compound annual growth rate (CAGR) of -0.9% to $10.9 billion by the end of the forecast period.
Scope
- Overview of ADHD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized ADHD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ADHD market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ADHD. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ADHD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ADHD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Table of Contents
- Abbreviations
- Related Reports
- Executive Summary
- Disease Overview
- Overview of ADHD
- ADHD SWOT Analysis
- Progression of ADHD
- Diagnosis and Classification of ADHD
- Epidemiology
- Diagnosed Prevalent Cases of ADHD, Men and Women, 2022-32
- Diagnosed Prevalent Cases of ADHD by Sex, 2022
- Diagnosed Prevalent Cases of ADHD by Presentation, Men and Women, 2022
- Diagnosed Prevalent Cases of ADHD by Severity, Men and Women, 2022
- Sources and Methodology: Diagnosed Prevalent Cases of ADHD
- Sources and Methodology: Diagnosed Prevalent Cases of ADHD by Presentation
- Sources and Methodology: Diagnosed Prevalent Cases of ADHD by Severity
- Current Treatment Options
- Treatment Paradigm
- Current Treatment Options
- Current Treatment Options: KOL Perspective
- Product Profile: Amphetamines (Vyvanse, Adderall, Mydayis, Dyanavel, Adzenys, Evekeo, Dexedrine, Xelstrym)
- Product Profile: Methamphetamines (Desoxyn)
- Product Profile: Methylphenidates (Concerta, Daytrana, Metadate CD, Methylin, Ritalin, Medikinet, Jornay PM, Aptensio XR, Quillivant XR, QuilliChew, Relexxii, Cotempla XR-ODT, Azstarys, Focalin)
- Product Profile: Alpha-2A Adrenergic Agonists (Intuniv; guanfacine hydrochloride ER)
- Product Profile: Noradrenergic Reuptake Inhibitors (Strattera and Qelbree)
- Unmet Needs and Opportunities
- Unmet Needs in ADHD
- Non-stimulant with a Stimulant-Comparable Efficacy Profile
- Products Providing Evening Coverage Without Sleep Disturbance
- Products Providing Dual Symptomatic Relief of Common ADHD Comorbidities
- Greater Awareness and Education of Prescribers
- R&D Strategies
- Trends in Clinical Trial Design in ADHD
- Trends in Deal-Making in ADHD
- Pipeline Assessment
- ADHD Pipeline Overview
- Late-Stage Pipeline Agents for ADHD
- Product Profile: Cingulate Inc's CTx-1301
- Product Profile: Axsome Therapeutics Inc's Solriamfetol Hydrochloride
- Product Profile: Otsuka Pharmaceutical Co's Centanafadine SR
- Product Profile: Neurocentria Inc's NRCT-101SR
- ADHD: Clinical Trials (Phase II/III) Overview
- Market Outlook
- ADHD Market Forecast
- Market Drivers and Barriers
- Market Drivers and Barriers: Global ADHD Medication Shortages
Appendix
- Primary Research: KOL Information
- Bibliography
- About the Authors
- Contact Us
관련자료
